Travis Slaba, PA
Medical · Harrisburg, SDNPI 1295732709
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.
Across 166 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488
- Phathom Pharmaceuticals, Inc.$300
- Lilly USA, LLC$286
- Dexcom, Inc.$275
- Novo Nordisk$230
- AstraZeneca$162
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,74699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $488 |
| Phathom Pharmaceuticals, Inc. | 14 | $300 |
| Lilly USA, LLC | 18 | $286 |
| Dexcom, Inc. | 25 | $275 |
| Novo Nordisk | 7 | $230 |
| AstraZeneca | 5 | $162 |
| Pfizer | 8 | $136 |
| Axsome Therapeutics, Inc. | 5 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $91 |
| Amgen | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Boston Scientific | 2 | $48 |
| Paratek Pharmaceuticals, Inc. | 2 | $46 |
| Novartis | 2 | $44 |
| Astellas Pharma US Inc | 2 | $42 |
| Merck | 2 | $40 |
| Medtronic | 2 | $34 |
| Boehringer Ingelheim | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,760 in reported general payments places this provider in the 85th percentile of 43 medical providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $66,100 |
| MounjaroTirzepatide | 57 | $63,186 |
| OzempicSemaglutide | 45 | $53,589 |
| EliquisApixaban | 54 | $49,856 |
| JardianceEmpagliflozin | 52 | $45,689 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 48 | $43,463 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $41,087 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $33,749 |
| XareltoRivaroxaban | 29 | $31,777 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $20,407 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 15 | $20,004 |
| SynjardyEmpagliflozin/Metformin Hcl | 17 | $16,012 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $14,997 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $12,735 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $26 | $105,164117 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $230 | $73,59360 claims |
| Lilly USA, LLCMounjaro | $286 | $63,18657 claims |
| PfizerEliquis, Paxlovid | $136 | $52,65371 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 43 medical providers in South Dakota.
Other medical in Harrisburg
- Molly SchooleyDakota Dunes$105K
- Crystal OberleDakota Dunes$7K
- David FeistWatertown$6K
- Sarah EngbersSioux Falls$4K
- Ashley AnzianoRapid City$4K
- Sarah BrendDakota Dunes$3K
- Becky EmersonSioux Falls$2K
- Jenna SchiefelbeinPierre$1K
- Cassandra SwannSioux Falls$755
- Jessica PowellSioux Falls$575
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.